Dr. David C. U’Prichard’s 35-year professional career spans academic research, senior R&D leadership at two global pharmaceutical companies, biotech company leadership, venture capital, and extensive experience on the boards of public and private U.S., UK, European and Indian companies.
In the last decade, Dr. U’Prichard has been a Venture Partner at Red Abbey Venture Partners, Apax Partners and Care Capital. From 1999 to 2003, he was CEO of 3-Dimensional Pharmaceuticals, which he took public in 2000 and sold to Johnson & Johnson. From 1997 to 1999, he served as Chairman of Research and Development at SmithKline Beecham. He worked for ICI/Zeneca from 1986 to 1997 as Executive Vice President and International Research Director from 1994 to 1997. While at Zeneca and SmithKline Beecham, Dr. U’Prichard oversaw the discovery and development of a number of successful drugs including Seroquel®, Accolate®, Avandia®, and Iressa®.
Following post-doctoral research at the Johns Hopkins University School of Medicine, Dr. U’Prichard was a tenured Associate Professor of Pharmacology and Neurobiology at Northwestern University Medical School. He has held academic appointments at Johns Hopkins University and the University of Pennsylvania, and is an Honorary Professor at the University of Glasgow.
Dr. U’Prichard received his PhD in Pharmacology from the University of Kansas, and his BS in Pharmacology from the University of Glasgow. He has authored more than 100 primary and review publications, was a founding co-editor of Molecular Neurobiology, and has served as a member of numerous editorial boards. Dr. U’Prichard is Chairman of the Board of Cyclacel Pharmaceuticals and a Board Member of Life Technologies (NASDAQ: LIFE), past Chairman of PennsylvaniaBio and has served on the Boards of BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, Ben Franklin Technology Partners, and the Bioethics Institute of the University of Pennsylvania.